CDC logo, Safer Healthier People CDC HomeCDC SearchCDC Health Topics A-Z
NIOSH - National Institute for Occupational Safety and Health

Search NIOSH  |  NIOSH Home  |  NIOSH Topics  |  Site Index  |  Databases and Information Resources  |  NIOSH Products  |  Contact Us




Benzene, 4 - allyl - 1,2 - (methylenedioxy) -

RTECS #: CY2800000

CAS #: 94-59-7

UPDATE: May 2009 MW: 162.20 MF: C10H10O2


NOTE:

TABLE OF CONTENTS:
  1. SYNONYMS:
  2. SKIN AND EYE IRRITATION DATA:
  3. MUTATION DATA:
  4. REPRODUCTIVE EFFECTS DATA:
  5. TUMORIGENIC DATA:
  6. ACUTE TOXICITY DATA:
  7. OTHER MULTIPLE DOSE DATA:
  8. REVIEWS:
  9. NIOSH DOCUMENTATION AND SURVEILLANCE:
  10. STATUS IN FEDERAL AGENCIES:
  11. REFERENCES:

SYNONYMS:

  1. 1,2 - Methylenedioxy - 4 - allylbenzene
  2. 1,3 - Benzodioxole, 5 - allyl -
  3. 1 - Allyl - 3,4 - methylenedioxybenzene
  4. 4 - Allyl - 1,2 - methylenedioxybenzene
  5. 4 - Allylpyrocatechol formaldehyde acetal
  6. 5 - (2 - Propenyl) - 1,3 - benzodioxole
  7. 5 - Allyl - 1,3 - benzodioxole
  8. Allylcatechol methylene ether
  9. Allyldioxybenzene methylene ether
  10. Allylpyrocatechol methylene ether
  1. Benzene, 1,2 - methylenedioxy - 4 - allyl -
  2. RCRA waste number U203
  3. Rhyuno oil
  4. Safrol
  5. Safrol glass
  6. Safrole
  7. Safrole MF
  8. Shikimole
  9. Shikomol
  10. m - Allylpyrocatechin methylene ether


SKIN AND EYE IRRITATION DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
skin
rabbit 		500 mg/24 hour moderate FCTXAV 12,983,1974


MUTATION DATA AND REFERENCES:

SYSTEM TEST ROUTE/
ORGANISM/
TISSUE 		DOSE REFERENCE
body fluid assay rat
ovary 		400 mg/kg MUREAV 143,263,1985
cytogenetic analysis hamster lung 75 mg/L PMRSDJ 5,427,1985
cytogenetic analysis hamster ovary 83,330 µg/L PMRSDJ 5,443,1985
cytogenetic analysis oral
rat 		625 mg/kg/5 day- continuous CRNGDP 19,141,1998
DNA adduct intraperitoneal
mouse 		80 mg/kg CRNGDP 5,1613,1984
DNA adduct oral
rat 		10 mg/kg CRNGDP 19,141,1998
DNA damage Bacillus subtilis 20 µL/disc PMRSDJ 1,175,1981
DNA damage hamster ovary 1 mmol/L PMRSDJ 5,367,1985
DNA damage human other cell types 4 mmol/L MUREAV 468,213,2000
DNA damage mouse lymphocyte 1 mmol/L MUREAV 203,155,1988
DNA damage rat liver 500 µmol/L MUREAV 189,69,1987
DNA inhibition human fibroblast 100 µmol/L MUREAV 183,89,1987
DNA inhibition intraperitoneal
mouse 		640 mg/kg MUREAV 37,67,1976
DNA repair Escherichia coli 25 mg/L JJIND8 62,873,1979
DNA repair other microorganisms 1 mmol/L (-enzymatic activation step) TOXID9 72,227,2003
DNA repair Saccharomyes cerevisiae 100 mg/L PMRSDJ 1,502,1981
unscheduled DNA synthesis human HeLa cell 10 µL/L PMRSDJ 5,347,1985
unscheduled DNA synthesis oral
rat 		1 gm/kg MUREAV 320,189,1994
unscheduled DNA synthesis rat liver 100 µmol/L CNREA8 42,3010,1982
host-mediated assay mouse
Salmonella typhimurium 		5,500 mg/kg JJIND8 62,911,1979
mutation in microorganisms Escherichia coli 5 gm/L (+enzymatic activation step) PMRSDJ 1,219,1981
mutation in microorganisms human lymphocyte 625 mg/L (+enzymatic activation step) PMRSDJ 5,497,1985
mutation in microorganisms mouse lymphocyte 54,800 µg/L (+enzymatic activation step) PMRSDJ 5,587,1985
mutation in microorganisms mouse embryo 250 mg/L (+enzymatic activation step) PMRSDJ 5,639,1985
mutation in microorganisms Salmonella typhimurium 50 µg/plate (+enzymatic activation step) NTIS** AD-A116-715
mutation in microorganisms Salmonella typhimurium 100 µg/plate (-enzymatic activation step) BJCAAI 37,873,1978
mutation in microorganisms Saccharomyes cerevisiae 21,920 µg/L (-enzymatic activation step) PMRSDJ 5,271,1985
mutation in microorganisms Saccharomyes cerevisiae 7,400 µg/L (+enzymatic activation step) PMRSDJ 5,257,1985
mutation in microorganisms Saccharomyes cerevisiae 34 mg/L/16 hour MUTAEX 20,105,2004
gene conversion and mitotic recombination Saccharomyes cerevisiae 175 ppm JJIND8 62,901,1979
mutation in mammalian somatic cells mouse lymphocyte 15,400 µg/L PMRSDJ 1,580,1981
morphological transform hamster kidney 80 µg/L BJCAAI 37,873,1978
morphological transform hamster embryo 10 ppm IJCNAW 19,642,1977
morphological transform mouse embryo 100 mg/L PMRSDJ 5,659,1985
morphological transform mouse fibroblast 0.1 pph/21 day (-enzymatic activation step) EMMUEG 37,231,2001
morphological transform oral
rat 		450 mg/kg CNREA8 40,1157,1980
other mutation test systems hamster ovary 162 mg/L PMRSDJ 5,359,1985
other mutation test systems oral
rat 		625 mg/kg/5 day- continuous CRNGDP 19,141,1998
sister chromatid exchange hamster ovary 50 mg/L PMRSDJ 5,413,1985
sister chromatid exchange hamster lung 500 µmol/L PMRSDJ 5,469,1985
sister chromatid exchange oral
rat 		100 mg/kg CRNGDP 19,141,1998
sex chromosome loss and nondisjunction Aspergillus nidulans 5,500 mg/L MUREAV 147,288,1985
sex chromosome loss and nondisjunction Saccharomyes cerevisiae 25 mg/L PMRSDJ 1,468,1981
specific locus test oral
Drosophila melanogaster 		500 µmol/L PMRSDJ 5,313,1985
specific locus test oral
Drosophila melanogaster 		0.125 mmol/L/48 hour- continuous MUREAV 582,87,2005


REPRODUCTIVE EFFECTS DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
intraperitoneal
mouse 		lowest published toxic dose: 1 gm/kg (5 day male) Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) PMRSDJ 1,712,1981


TUMORIGENIC DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
oral
mouse 		lowest published toxic dose: 22 gm/kg/90 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors 		CNREA8 39,4378,1979
oral
mouse 		lowest published toxic dose: 480 mg/kg (12-18 day pregnant) Tumorigenic: Neoplastic by RTECS criteria

Reproductive: Tumorigenic effects: Transplacental tumorigenesis

Kidney, Ureter, and Bladder: Kidney tumors 		CNREA8 39,4378,1979
oral
mouse 		toxic dose : 210 gm/kg/52 week- continuous Tumorigenic: Neoplastic by RTECS criteria

Liver: Tumors 		CNREA8 37,1883,1977
oral
mouse 		toxic dose : 212 gm/kg/1 year- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors

Liver: Angiosarcoma 		CNREA8 43,1124,1983
oral
mouse 		toxic dose : 187 gm/kg/56 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors 		CNREA8 33,590,1973
oral
mouse 		toxic dose : 132 gm/kg/81 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors 		JNCIAM 42,1101,1969
oral
mouse 		toxic dose : 121 gm/kg/36 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors 		JJIND8 67,365,1981
oral
mouse 		toxic dose : 175 gm/kg/52 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors 		JJIND8 67,365,1981
oral
mouse 		toxic dose : 252 gm/kg/75 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors 		JJIND8 67,365,1981
oral
mouse 		toxic dose : 82,602 mg/kg/81 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors 		DIGEBW 19,42,1979
oral
mouse 		toxic dose : 56 gm/kg/52 week- continuous Tumorigenic: Neoplastic by RTECS criteria

Liver: Tumors 		CNREA8 43,5163,1983
oral
rat 		lowest published toxic dose: 200 gm/kg/94 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Tumors

Liver: Tumors 		CNREA8 37,1883,1977
oral
rat 		toxic dose : 183 gm/kg/2 year- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors 		FEPRA7 20,287,1961


ACUTE TOXICITY DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
intraspinal
rat 		lowest published toxic dose: 10 mg/kg Cardiac: Change in rate

Vascular: BP lowering not characterized in autonomic section 		JOETD7 45,183,1995
intravenous
rat 		lowest published toxic dose: 10 mg/kg Cardiac: Change in rate

Vascular: BP lowering not characterized in autonomic section 		JOETD7 45,183,1995
intravenous
rabbit 		lowest published lethal dose: 200 mg/kg Vascular: BP elevation not characterized in autonomic section

Vascular: BP lowering not characterized in autonomic section 		AEXPBL 35,342,1895
oral
mouse 		lethal dose (50 percent kill): 2,350 mg/kg Behavioral: Somnolence (general depressed activity)

Behavioral: Ataxia 		FCTXAV 2,327,1964
oral
rat 		lethal dose (50 percent kill): 1,950 mg/kg Behavioral: Somnolence (general depressed activity) TXAPA9 7,18,1965
oral
rabbit 		lowest published lethal dose: 1 gm/kg Peripheral Nerve and Sensation: Spastic paralysis with/without sensory change

Behavioral: Ataxia

Kidney, Ureter, and Bladder: Other changes in urine composition 		AEXPBL 35,342,1895
subcutaneous
mouse 		lethal dose (50 percent kill): 1,020 mg/kg Behavioral: Excitement SIZSAR 3,73,1952
subcutaneous
rabbit 		lowest published lethal dose: 1 gm/kg Peripheral Nerve and Sensation: Spastic paralysis with/without sensory change

Behavioral: Somnolence (general depressed activity)

Nutritional and Gross Metabolic: Body temperature decrease 		AEXPBL 35,342,1895
skin
rabbit 		lethal dose (50 percent kill): >5 gm/kg N/R FCTXAV 12,983,1974


OTHER MULTIPLE DOSE DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
oral
mouse 		lowest published toxic dose: 15 gm/kg/60 day- intermittent Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field TXAPA9 7,18,1965
oral
rat 		lowest published toxic dose: 74,375 µg/kg/85 week- continuous Liver: Other changes

Liver: Changes in liver weight 		TXCYAC 7,307,1977
subcutaneous
mouse 		lowest published toxic dose: 26.4 mg/kg/4 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Liver: Other changes 		TCPHP* -,247,2000
subcutaneous
mouse 		lowest published toxic dose: 264 mg/kg/4 week- intermittent Lung, Thorax, or Respiration: Tumors TCPHP* -,247,2000


REVIEWS:

ORGANIZATION STANDARD
REFERENCE
International Agency for Research on Cancer (IARC) Cancer Review Animal Sufficient Evidence IMEMDT 10,231,1976
International Agency for Research on Cancer (IARC) Cancer Review Human No Adequate Data IMEMDT 10,231,1976
International Agency for Research on Cancer (IARC) Cancer Review Group 2B IMSUDL 7,56,1987
TOXICOLOGY REVIEW
FCTOD7 40,851,2002
TOXICOLOGY REVIEW
CTRRDO 60,1171,1976
TOXICOLOGY REVIEW
MUREAV 574,124,2005
TOXICOLOGY REVIEW
MUREAV 574,124,2005
TOXICOLOGY REVIEW
MUREAV 588,88,2005
TOXICOLOGY REVIEW
MUREAV 627,59,2007
TOXICOLOGY REVIEW
MUREAV 584,1,2005
TOXICOLOGY REVIEW
MUREAV 608,136,2006


STANDARDS AND REGULATIONS:

ORGANIZATION STANDARD
REFERENCE
N/R N/R N/R


NIOSH DOCUMENTATION AND SURVEILLANCE:

ORGANIZATION STANDARD or SURVEY
REFERENCE
National Occupational Hazard Survey 1974 National Occupational Hazard Survey 1974: Hazard Code: 83472;
Number of Industries 1;
Total Number of Facilities 68;
Number of Occupations 1;
Total Number of Employees Exposed 68
National Occupational Exposure Survey 1983 National Occupational Exposure Survey 1983: Hazard Code: 83472;
Number of Industries 4;
Total Number of Facilities 74;
Number of Occupations 5;
Total Number of Employees Exposed 6,475;
Total Number of Female Employees Exposed 5,761


STATUS IN FEDERAL AGENCIES:

ORGANIZATION
REFERENCE
EPA GENETOX PROGRAM 1988, Positive: Carcinogenicity-mouse/rat; SHE-clonal assay
EPA GENETOX PROGRAM 1988, Positive: Host-mediated assay; E coli polA without S9
EPA GENETOX PROGRAM 1988, Positive: E coli polA with S9; S cerevisiae-homozygosis
EPA GENETOX PROGRAM 1988, Negative: Histidine reversion-Ames test
EPA GENETOX PROGRAM 1988, Negative: D melanogaster Sex-linked lethal
EPA GENETOX PROGRAM 1988, Negative: In vitro UDS-human fibroblast
EPA GENETOX PROGRAM 1988, Inconclusive: Mammalian micronucleus; Sperm morphology-mouse
EPA TSCA Section 8(b) CHEMICAL INVENTORY
Used as a cosmetic and perfume ingredient
EPA TSCA Section 8(d) unpublished health/safety studies
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
NTP 11th Report on Carcinogens,2004:Reasonably anticipated to be a human carcinogen


REFERENCES:

CODEN
REFERENCE
AEXPBL Archiv fuer Experimentelle Pathologie und Pharmakologie. (Leipzig, Ger. Dem. Rep.) V.1-109, 1873-1925. For publisher information, see NSAPCC.
BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947-
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941-
CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980-
CTRRDO Cancer Treatment Reports. (Washington, DC) V.60-71, 1976-87. For publisher information, see JNCIEQ.
DIGEBW Digestion. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.1- 1968-
EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987-
FCTOD7 Food and Chemical Toxicology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.20- 1982-
FCTXAV Food and Cosmetics Toxicology. (London, UK) V.1-19, 1963-81. For publisher information, see FCTOD7.
FEPRA7 Federation Proceedings, Federation of American Societies for Experimental Biology. (Bethesda, MD) V.1-46, 1942-87.
IJCNAW International Journal of Cancer. (International Union Against Cancer, 3 rue du Conseil- General, 1205 Geneva, Switzerland) V.1- 1966-
IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972-
IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979-
JJIND8 JNCI, Journal of the National Cancer Institute. (Washington, DC) V.61-79, 1978-87. For publisher information, see JNCIEQ.
JNCIAM Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher information, see JJIND8.
JOETD7 Journal of Ethnopharmacology. (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1979-
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-
MUTAEX Mutagenesis. (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1986-
NTIS** National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information.
PMRSDJ Progress in Mutation Research. (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.1- 1981-
SIZSAR Sapporo Igaku Zasshi. Sapporo Medical Journal. (Sapporo Igaku Daigaku, Nishi-17-chome, Minami-1-jo, Chuo-ku, Sapporo 060, Japan) V.3- 1952-
TCPHP* Toxicology and Clinical Pharmacology of Herbal Products Melanie Johns Cupp ed., Humana press, 2000.
TOXID9 Toxicologist. (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-
TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959-
TXCYAC Toxicology. (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1- 1973-

Used as a cosmetic and perfume ingredient

RTECS Compound Description:
   Tumorigen
   Mutagen
   Reproductive Effector
   Human Data
   Natural Product
   Primary Irritant

 Click Here for Additional Information about RTECS

NIOSH Home |  NIOSH Search  |  Site Index  |  Topic List |  Contact Us